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Abstract
The Src homology and collagen (Src) family of adaptor
proteins comprises six Shc-like proteins encoded by three
loci in mammals (Shc, Rai, and Sli). Shc-like proteins are
tyrosine kinase substrates, which regulate diverse signaling
pathways and cellular functions, including Ras and prolifer-
ation (p52/p46Shc), phosphatidylinositol 3-kinase and sur-
vival (p54Rai), and mitochondrial permeability transition
and apoptosis (p66Shc). Here, we report the identification,
cloning, and sequence characterization of a new member of
the Shc family that we termed RaLP. RaLP encodes a 69-kDa
protein characterized by the CH2-PTB-CH1-SH2 modularity,
typical of the Shc protein family, and expressed, among adult
tissues, only in melanomas. Analysis of RaLP expression
during the melanoma progression revealed low expression in
normal melanocytes and benign nevi, whereas high levels of
RaLP protein were found at the transition from radial
growth phase to vertical growth phase and metastatic
melanomas, when tumor cells acquire migratory competence
and invasive potential. Notably, silencing of RaLP expression
in metastatic melanomas by RNA interference reduced
tumorigenesis in vivo . Analysis of RaLP in melanoma signal
transduction pathways revealed that (a) when ectopically
expressed in RaLP-negative melanocytes and nonmetastatic
melanoma cells, it functions as a substrate of activated
insulin-like growth factor-1 and epidermal growth factor
receptors and increases Ras/mitogen-activated protein ki-
nase (MAPK) signaling and cell migration, whereas (b) its
silencing in RaLP-positive melanoma cells abrogates cell
migration in vitro , without affecting MAPK signaling,
suggesting that RaLP activates both Ras-dependent and
Ras-independent migratory pathways in melanomas. These
findings indicate that RaLP is a specific marker of metastatic
melanomas, a critical determinant in the acquisition of the
migratory phenotype by melanoma cells, and a potential
target for novel anti-melanoma therapeutic strategies.
[Cancer Res 2007;67(7):3064–73]
Introduction
The family of Src homology and collagen (Src) genes is an
example of the evolutionary success of signal transduction adaptor
proteins. Its complexity increased during evolution from one locus
in Drosophila to three loci in mammals (ShcA/Shc, ShcB/Sli, and
ShcC/Rai), which encode, due to alternative initiation codon usage
and splicing patterns, at least six Shc-like proteins, characterized
by an NH2-terminal phosphotyrosine-binding (PTB) domain, a
central region rich in proline and glycine residues (CH1) and a
COOH-terminal Src homologue 2 domain (SH2) in the presented
order (1). A second NH2-terminal collagen homology region (CH2)
is present in the longest isoform of Shc (p66Shc; ref. 2), in p64Rai
(3), and in p68Sli (4). The (CH2)-PTB-CH1-SH2 modularity is a
unique feature of Shc family members (1, 5).
Despite their structural similarity, genetic and biological
evidence indicate that the various Shc proteins are functionally
nonredundant and regulate functions as diverse as proliferation
(p52Shc), survival (p64Rai), and apoptosis and life span (p66Shc),
suggesting that they are critical determinants of cell homeostasis
(3, 5–8). Biochemically, they are all targets of activated tyrosine
kinases (TK) but regulate different signaling events, including the
activation of Ras (p52Shc), phosphatidylinositol 3-kinase (PI3K;
p64Rai), and the mitochondrial permeability transition (p66Shc;
refs. 3, 6, 9).
p52Shc proteins are ubiquitously expressed and are rapidly and
efficiently tyrosine phosphorylated by all TKs tested thus far (5).
Once phosphorylated, p52Shc facilitates recruitment of the SH2-
containing growth factor receptor binding protein 2 (Grb2)
adaptor protein to activated membrane receptors. The PTB
and/or SH2 domains of Shc bind to tyrosine-phosphorylated
receptors, whereas the SH2 of Grb2 binds to the tyrosine-
phosphorylated CH1 region of Shc. Grb2, in turn, is constitutively
complexed to Sos, a guanine nucleotide exchange factor of Ras.
Recruitment of the Grb2/Sos complex, by p52Shc, results in the
membrane relocalization of Sos, an event considered sufficient to
induce Ras activation. Association of phosphorylated Shc with
Grb2 may also lead to the activation Gab1, a potent activator of
PI3K signaling (10).
P66Shc functions in the intracellular pathway(s) that regulates
reactive oxygen species (ROS) metabolism and stress-induced
apoptosis (7). A fraction of the intracellular pool of p66Shc
localizes within mitochondria, where it generates ROS and
regulates cytochrome c release (9, 11).
p64/p52Rai is expressed in the central nervous system (12–16)
where it functions as a specific substrate of the RET receptor (3). Rai
proteins form a constitutive complex with the p85 subunit of PI3K,
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which is then recruited to ligand-activated RET receptor. Upon
phosphorylation, RET stimulates neuronal cell survival by increas-
ing PI3K activation. Notably, Rai activates PI3K also in the absence
of growth factors, such as after hypoxic or oxidation insults (17).
P46Shc is a ubiquitously expressed mitochondrial protein (18);
p68Sli is a cytosolic protein predominantly expressed in neurons
(12, 15). Their functions remain unknown.
We report here the identification and preliminary functional
characterization of a new Shc family member.
Materials and Methods
Cloning of RaLP
Human cDNAs containing the full-length open reading frame (ORF) was
obtained by reverse transcription-PCR (RT-PCR) from total RNA of normal
human and mouse skin. Oligonucleotides 1 (5¶-TTTATGCAACAG-
TATCCTGTTT-3¶) and 2 (5¶-CTTCAATACTGTCATTTGTT-3¶) were used to
clone the human gene; oligonucleotides 3 (5¶-CTGCTAAGGCTATGCGA-
GAA-3¶) and 4 (5¶-CCGGGAGTCATCATTTCTT-3¶) were used to clone the
mouse counterpart.
Cell Culture, Infection, and Transfection
The melanoma WM115 and WM266-4 and the fibrosarcoma HT-1080 cell
lines were purchased from the American Type Culture Collection
(Manassas, VA), whereas IGR-37, IGR-39, COLO-679, IGR-1, and RPMI-
7951 were from Deutsche Sammlung von Mikroorganismen (Braunschweig,
Germany). The melanoma COLO-853 cell line was purchased from Interlab
Cell Line Collection (Genova, Italy). WM1575 were courtesy of M. Herlyn
(The Wistar Institute, Philadelphia, PA). Cells were maintained as suggested
by the suppliers. Normal human melanocytes were generated by dispase
(Invitrogen, Carlsbad, CA) treatment of normal skin. The epidermis was
disaggregated by trypsin-EDTA (Cambrex, Charles City, IA), and cells were
seeded in McCoy’s (Invitrogen) medium supplemented with 2% FCS, insulin
(Roche, Indianapolis, IN), cholera toxin, 12-O-tetradecanoylphorbol-13-
acetate, transferrin, hydrocortisone (Sigma-Aldrich, St. Louis, MO), stem
cell factor, and fibroblast growth factor (Peprotech, Rocky Hill, NJ) and
grown for several weeks.5 Transfection of the Phoenix packaging cell line
and infection of target cells were done as described (19), using retroviral
pBABE-based vectors carrying the human RaLP (pBABE-RaLP) and p52/
p46Shc (pBABE-Shc) cDNAs. For the RNA interference assays, 9  104
WM266-4 cells per well were plated, in triplicate, in six-well clusters and
transfected with Oligofectamine (Invitrogen) and 200 nmol/L small
interfering RNAs [siRNA-RaLP(1), 5¶-CCCGGCCACUUUGCUGAGUCU-3¶;
siRNA-RaLP(2), 5¶UCAAUGAGAUCACUGGAUUUU-3¶: Luciferase, 5¶-
CGUACGCGGAAUACUUCGA-3¶ or green fluorescent protein (GFP), 5¶-
GGCTACGTCCAGGAGCGCA-3¶].
Cell Proliferation and Migration Assays
Proliferation assays. RaLP-siRNA– and Luc-siRNA–transfected WM266-
4 cells (9  104) were plated, in triplicate, in six-well clusters and cultured
for 24, 48, and 72 h in medium containing 10% FCS. Cell viability was
measured by trypan blue dye exclusion. Each experiment was done in
triplicate, and means F SD are presented.
Migration assays. siRNA-transfected WM266-4 cells (5  104) were
seeded into the upper chamber of modified Boyden chambers (Transwell,
Corning-Costar, Cambridge, MA; 0.8-Am filter pore diameter) at the
indicated time points in 0.1% bovine serum albumin containing medium.
In the bottom chamber, 10% fetal bovine serum was added to the medium,
and the chambers were placed in humidified incubator for 24 h.
Nonmigrating cells were removed with a flattened swab, and migrating
cells on the underside of the chamber were stained with crystal violet
solution. The extent of migration was determined by destaining migrated
cells with 10% acetic acid and measuring the absorbance at k595 nm. Data
are given as mean F SE.
Immunoprecipitation, In vitro Binding Assays, and Western
Blot Analysis
Cell cultures were serum starved for 48 h and treated with epidermal
growth factor (EGF; Peprotech; 10 ng/mL) or insulin-like growth factor-1
(IGF-1; Peprotech; 100 ng/mL) for 10 min, if not otherwise specified. For
immunoprecipitations, cell lysates were incubated with antibodies against
RaLP, IGF-1 receptor (IGF-1R), EGF receptor (EGFR), and Shc. For in vitro
binding assays, total protein lysates (1.5 mg) were incubated with 50 Ag of
the appropriate glutathione S-transferase (GST) fusion protein. The GST-
Raf assay was done as described (20). The following antibodies were used:
anti-EGFR (Upstate Biotechnology, Lake Placid, NY); anti-IGF-1R and anti–
extracellular signal-regulated kinase 1/2 (ERK1/2; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA); anti-vinculin (Sigma-Aldrich); anti-Grb2, anti-pTyr,
and anti-Ras (BD Transduction Laboratories, San Jose, CA); anti-AKT, anti–
phosphorylated AKT (p-AKT; Ser473), and anti–phosphorylated mitogen-
activated protein kinase (p-MAPK; Cell Signaling Technology, Danvers, MA).
Anti-Shc antibodies have been previously generated in our laboratory and
used as detailed (2). Anti-RaLP polyclonal antibodies were raised against
the CH2, CH1, and SH2 domains cloned into the pGEX-2T (Invitrogen)
plasmid and expressed in bacteria, as described (2).
Immunofluorescence Analysis and Cell Fractionation
Immunofluorescence analysis was done as described (21). Briefly, cells
were seeded on sterile coverslips, fixed in paraformaldehyde, permeabilized,
stained with anti-RaLP antibody, and analyzed by epifluorescence.
Cell fractionation. Cell pellets were resuspended in ice-cold 5 mmol/L
PIPES (pH 8), 1 mmol/L EGTA, 2 mmol/L DTT, and protease inhibitors;
0.5% NP40 is gently added, and lysates were centrifuged at 4jC to separate
supernatant (cytoplasm) from pellet (nuclei). The separation of membrane
and cytoplasmic fractions was done by the phase separation method using
Triton X-114 (22). Briefly, cells were lysed in 1% Triton X-114, 10 mmol/L
Tris and supernatant layered onto 6% sucrose buffer. After centrifugation,
the cytoplasmic-containing fraction was recovered as aqueous phase,
whereas the Triton X-114 phase, containing the membrane fraction, was
recovered as a small gelatinous pellet underneath the sucrose cushion.
Equal amounts of protein lysates (25 Ag) of each cellular fraction were
loaded per lane and analyzed by SDS-PAGE.
MAPK and AKT Activation Assays
Cells were serum starved for 24 h and treated with 100 ng/mL IGF-1 or
10 ng/mL EGF for 10, 30, and 60 min (p-MAPK immunoblot) or 30, 60, and
120 min (p-AKT immunoblot), before lysis; 15 Ag of total lysate were loaded
and probed with anti-p-MAPK, ERK1/2, p-AKT, and AKT antibodies.
Tissue Microarrays
For the large-scale screening study, three tissue microarrays (TMA1–
TMA3) were specifically designed. Human specimens derived from formalin-
fixed and paraffin-embedded tissue specimens of normal and malignant
origin were analyzed. The samples were provided by the IEO Department of
Pathology, Ospedale Maggiore (Novara), Presidio Ospedaliero (Vimercate),
and Ospedale Sacco (Milano). Design and engineering of TMAs and in situ
hybridization (ISH) were conducted as previously described (23). The TMAs
contained 43 gastrointestinal carcinomas, 31 breast carcinomas, 25 lung
carcinomas, 25 prostate carcinomas, 17 sarcomas, 12 lymphomas, 28 ovarian
cancers, 25 metastatic melanomas, 15 larynx carcinomas, 19 glioblastomas,
8 papillary carcinomas, 15 carcinomas of the urinary tract, and 11 sem-
inomas. The melanoma progression TMA includes specimens obtained from
nevi, radially growing and vertically growing melanomas and metastasis.
Gene expression levels were assessed by ISH using S35-UTP–labeled
sense and antisense riboprobes, as described (23). Gene expression levels
were evaluated by counting the number of grains per cell, and cells were
scored unequivocally positive when containing >25 grains.
Immunohistochemical staining was done with anti-CH2 RaLP antibody
(1:200 dilution) followed by detection with the DAKO EnVision Plus system,
as previously described (23).5 G. Giardina, unpublished data.
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S.c. Implantation of Metastatic Melanoma Cells
Nude athymic mice (6–8 weeks of age; HDS-athymic nude mice, Harlan,
Udine, Italy) were implanted s.c. in the right flank either with 106 control
GFP-siRNA or RaLP(1)-siRNA WM266-4 cells. The animals were kept under
pathogen-free conditions in positive-pressure cabinets and observed thrice
a week for the visual appearance of tumors at injection sites. Tumor growth
was measured using calipers. Tumor diameter was calculated as the mean
value between the shortest and longest diameter. Mice were sacrificed
when tumor mass was reaching 10% of the mouse weight. Tumors were
excised, and protein lysates were prepared according to established
procedures.
Results
Identification of RaLP. TBLASTn analysis of the human and
mouse genome with Shc, Rai, and Sli proteins from different
organisms led to the identification of a putative new member of
the Shc gene family on human 15q21.1-q21.2 and mouse 2F1
chromosomes. The longest ORF of the homology-based recon-
structed cDNAs predicts a protein with a CH2-PTB-CH1-SH2
modularity, typical of Shc-like proteins (Fig. 1A). Because the first
evidences for the existence of this new gene were found searching
with the Fugu rubripes Rai protein, this novel ORF was named
RaLP ( for Rai-like protein).
Human and mouse cDNAs containing the full-length ORFs were
obtained by RT-PCR from total RNA of normal human and mouse
skin, respectively (Genbank accession nos. AY464565 and
AY464564). Their nucleotide sequence revealed an ORF of 630
and 626 AA, respectively, encoding for a putative protein of about
69 kDa. The alignment of human and mouse RaLP and human
p66Shc, p64Rai, and p68Sli protein sequences is shown in Fig. 1B .
Figure 1. A, RaLP protein organization. The RaLP protein product is composed of two phosphotyrosine-binding domains, one located at the NH2 terminus of the
protein (PTB) and one at the COOH terminus (SH2). The CH1 region links the two domains; a CH2 region resides at the most NH2-terminal portion of the molecule.
Tyr374/375 and Tyr465 are indicated by red dots in the CH1 region. B, alignment of the proteins belonging to the Shc family. Human and mouse RaLP proteins are
aligned with human p66Shc, p64Rai, and p68Sli. Red asterisks, phosphotyrosine-binding pocket residues of the PTB and SH2 domains, which are strictly conserved
among the four paralogues. Blue asterisks, on the contrary, charged residues directly involved in the PtdIns(4,5)P2 and PtdIns(3,4,5)P3 binding, which are not
maintained in RaLP. Red squares, perfectly conserved CH1 tyrosine residues. Black box, points out that the amino acid stretch crucial for the interaction with the AP2
complex is entirely retained in Rai and Sli proteins but completely lost in RaLP. Red head arrows, identify S37, S76, and T142 residues as putative target residues
for phosphorylation by different kinases in RaLP.
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RaLP is the most distant relative among the human Shc
paralogues, with an overall identity at protein level of 37%, 41%,
and 45% with Sli, Rai, and Shc, respectively (the overall identity
among Shc, Sli, and Rai ranges from 44% to 47%). With respect to
its modules, the RaLP PTB and SH2 domains are the most
conserved (69–76% identity for the PTB region, 55–69% identity for
the SH2 region, 18–24% identity for the CH1 region, and 17–25%
identity for the CH2 region). The phosphotyrosine-binding pocket
residues of the Shc PTB and SH2 domains, as identified by nuclear
magnetic resonance, are highly conserved among the four Shc
paralogues (Fig. 1B, red asterisks). The charged residues involved in
the binding of the Shc PTB domain to phospholipids, which are
conserved in the other members, are partially lost in RaLP (blue
asterisks). In the CH1 region, the three tyrosine residues, which in
the context of Shc and Rai are phosphorylated and bind Grb2, are
conserved in RaLP, both in terms of relative position and adjacent
amino acid context (red squared ‘‘P’’ above the alignment). The
RDLFDMKPFE sequence of the Shc CH1 region, which is critical for
its interaction with the AP2 complex, is maintained in Rai and Sli
proteins but not in RaLP (black box). In the RALP CH2 region,
neither the S36 residue nor the EEW motif of p66Shc, which is
critical for the activation of its proapoptotic function (8, 9), is
conserved. These data suggest that some Shc properties (receptor
and Grb2 binding) might be retained in RaLP.
RaLP RNA expression is restricted to invasive and meta-
static melanomas. To investigate the pattern of RaLP expression in
adult tissues, we analyzed levels of RaLP mRNA by ISH on a set of
TMAs, which include a series of 274 of the most common tumor
types and 160 normal samples. RaLP expression was detected only in
melanomas (10 of 17 cases; Fig. 2A). Serial sections of the same TMA
hybridized with a h-actin probe ensured for RNA quality in the
analyzed tissue samples (Fig. 2A). To investigate when RaLP
becomes expressed during melanoma genesis and progression, we
extended our analysis to a larger series of 74 pigmented lesions,
including nevi (35 samples), radial growth phase (RGP; 10 samples),
vertical growth phase (VGP; 12 samples), and metastatic (17
samples) melanomas. Results showed no expression of RaLP mRNA
in nevi and RGP melanomas, whereas 50% of VGP and 47% of
metastatic melanomas were highly positive (Fig. 2B and C). TMA
data were confirmed by quantitative RT-PCR analysis, which showed
low RaLP expression in nevi, intermediate in RGP melanomas, and
increasingly higher in VGP and metastatic melanomas (Fig. S1A). It
seems, therefore, that RaLP expression appears in melanomas when
tumor cells acquire the ability to invade the underneath tissues.
Identification of the RaLP protein in metastatic melanomas.
We generated anti-RaLP polyclonal antibodies in rabbits using
bacterially expressed RaLP CH2 region. The resulting immune sera
(a) specifically reacted with in vitro translated RaLP cDNA (data not
shown), (b) recognized a protein of f69 kDa in HeLa cells
transiently transfected with a RaLP expression vector (Fig. 3A), (c)
gave a specific immunofluorescence signal in WM266-4 melanoma
cells (compared with same cells after RaLP silencing; Fig. S1B), and
(d) did not cross-react with endogenous Shc proteins (Fig. S1C).
Western blot analysis of a series of tumor cell lines showed RaLP
expression only in metastatic melanomas (Fig. 3A, middle). Analysis
of primary cultures of two early vertical growth melanoma samples
(WM115 and IGR-39) and their metastatic counterparts (WM266-4
and IGR-37) showed higher levels in the metastatic cells (Fig. 3A,
Figure 2. Identification of RaLP transcripts on normal and tumoral tissues. A, RaLP mRNA levels were analyzed by ISH on a set of TMA (TMA1, TMA2, and TMA3),
which include 274 tumor specimens and 160 normal tissues. B, incidence of RaLP expression in a panel of melanocytic samples representing the different stages
of melanoma progression. C, bright (top ) and dark (bottom ) field images of RaLP-hybridized benign nevi (N ), RGP, VGP melanomas, and metastasis (MM ). Positive
cells are identified by the presence of silver grains.
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bottom). Immunohistochemical analysis of RaLP protein expression
in paraffin-embedded samples of metastatic melanomas revealed
intense and uniform intracellular staining in all tumor cells (Fig. 3B ;
the brownish staining corresponds to RaLP expression by tumor
cells, whereas the blue areas represent the peritumoral normal
stroma).
RaLP is expressed at low levels in normal melanocytes. We
then investigated RaLP expression in normal melanocytes, by
analysis of human normal skin and primary cultures of melano-
cytes. Quantitative RT-PCR analysis of normal skin and in vitro
cultured melanocytes (three samples each) revealed the presence of
RaLP transcripts in all samples, although at higher levels in the
cultured melanocytes (Fig. S1A). ISH and immunohistochemical
analysis of sections of normal skin (15 samples) revealed negativity
of RaLP mRNA and protein, respectively, in all the cells of the
epidermal and dermal layers (data not shown). To ensure that RaLP
expression in skin melanocytes had not escaped our analysis,
several normal skin biopsies were processed for RaLP ISH and
immunohistochemistry and then analyzed in bright field to identify
resident brownish, melanin-containing melanocytes (data not
shown). Immunofluorescence analysis of in vitro proliferating
melanocytes showed low, yet consistently detectable, levels of RaLP
protein, compared with RaLP-transduced primary melanocytes or
metastatic melanomas (Fig. 3C). Together, these data suggest that
RaLP expression is very low in normal resident melanocytes, and
that it increases significantly when they are grown in vitro .
The pattern of anti-RaLP immunofluorescence staining (Fig. 3C)
suggests that RaLP is a cytoplasmic protein (confirmed by nucleus-
cytoplasmic fractionations; Fig. 3D). Further subcellular fractiona-
tions showed that the majority of the RaLP protein is localized in
the cytosol, with onlyf5% in membranes. Notably, the membrane
fraction of the RaLP protein displays retarded gel migration
mobility, which might be due to posttranslational modifications
(Fig. 3D).
Down-regulation of RaLP expression in melanoma cells
abrogates cell migration in vitro and prevents tumor growth
in vivo . To investigate the role of RaLP in the growth
and migratory phenotypes of metastatic melanomas, we
Figure 3. RaLP is specifically expressed
in melanomas, and it is localized in the
cytoplasm of the cells. A, left, anti-CH2
RaLP polyclonal antibody and anti-vinculin
(used as loading control) staining of
WM266-4 melanoma cells; HeLa and
HeLa cells transiently transfected with
a RaLP-expressing vector (HeLa-RaLP)
served as negative and positive controls,
respectively. HeLa-RaLP and WM266-4
cells express comparable levels of RaLP
protein. Middle, RaLP protein expression
in metastatic melanoma (COLO853,
RPMI-7951, COLO679, WM35, and
IGR-1), kidney epithelial (Phoenix), and
fibrosarcoma (HT-1080) cell lines. Right,
primary melanoma cell lines (WM115 and
IGR-39) show low levels of RaLP, while
the metastatic counterparts (WM266-4
and IGR-37) higher levels. B, RaLP
immunohistochemical staining of
metastatic melanoma biopsies. All
neoplastic cells of the tissue reveal intense
and uniform intracellular staining for
RaLP protein (brownish staining ). The blue
RaLP-negative areas represent the
peritumoral stroma. C, anti-CH2 RaLP
staining on normal melanocytes,
RaLP-overexpressing melanocytes, and
melanoma cultures. D, normal
melanocytes, RaLP-overexpressing
melanocytes, and melanoma cells were
fractionated in nuclei, cytoplasm, and
membranes according to standardized
protocols (see Materials and Methods).
Immunoblots of fractionated lysates were
probed with anti-CH2 RaLP antibody to
detect the intracellular localization of
the protein.
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down-regulated RaLP expression by siRNAs. Transfection of RaLP-
specific siRNAs into WM266-4 metastatic melanoma cells induced
marked reduction of RaLP expression, compared with controls
(luciferase-specific siRNAs; Fig. 4A). RaLP silencing did not affect
levels of Shc proteins (Fig. S2A ), did not provoke gross
modifications on cell morphology (Fig. S2B), and exerted no
effects on cell proliferation, as determined by cell count (Fig. 4B),
cell cycle analysis, and bromodeoxyuridine incorporation (data not
shown). Likewise, anti-caspase-3 staining and terminal deoxynu-
cleotidyl transferase–mediated nick-end labeling assay did not
show significant effects of RaLP silencing on apoptosis (<5% at all
time points; data not shown). To investigate the role of RaLP in cell
motility, RaLP-siRNA– and Luc-siRNA–transfected WM266-4 cells
were seeded in a modified Boyden chamber (Transwell) in serum-
free conditions and allowed to migrate towards serum. Serum-
driven cell migration was almost completely inhibited in the
presence of RaLP-siRNAs, compared with controls (Fig. 4C).
Similar results were obtained using different RaLP-siRNA and
control-siRNAs [RaLP(2)-siRNA and GFP-siRNA; Fig. 4A] and
different metastatic cells (IGR-37; data not shown), thus suggesting
that continuous RaLP expression is required for in vitro migration
of invasive melanoma cells.
We then tested if RaLP silencing blocks the tumorigenic
potential of metastatic melanoma in vivo . Cells from the same
experiment as in Fig. 4A [WM266-4 cells treated with RaLP(1)-
siRNA or GFP-siRNA] were injected s.c. into nude mice. Tumor
formation was monitored thrice a week for 3 weeks. RaLP down-
regulation correlated with markedly reduced tumor growth
(Fig. 4D). Notably, Western blotting of control and RaLP-silenced
tumors taken at the end of the experiment revealed equal levels
of RaLP expression (Fig. 4D), suggesting that the residual growth of
the RaLP-siRNA tumors was due to emergency of rare RaLP-
expressing cells. Together, these data indicate that RaLP expression
is critical for the tumorigenic potential of metastatic melanoma
in vivo .
RaLP is a substrate of the IGF-1R and EGFR in melanoma
cells. EGF and IGF-1 play a critical role in the maintenance of
growth, survival, and migration of melanoma cells in vivo (24–29).
To investigate the role of RaLP in IGF-1 and EGF signaling, we used
IGR-37 metastatic melanoma cells, which express RaLP (Fig. 3A)
Figure 4. Inhibition of RaLP expression by RNA interference affects migration in vitro and tumorigenesis in vivo of melanoma cells. A, Western blot analysis of
RaLP(1)-siRNA, RaLP(2)-siRNA, GFP-siRNA, and Luc-siRNA WM266-4 cells. Lysates were extracted at 24, 48, and 72 h upon siRNA duplex transfection and probed
with anti-CH2 RaLP and anti-vinculin, as control, antibodies. B, proliferation assay. WM266-4 cells were plated in six-well clusters (90,000 per well) and counted
in triplicate for three days after RNA interference. Points, mean from three separate determinations; bars, SD. C, migration assay. Cells (50,000 per well) were plated in
a Transwell chamber and allowed to migrate as detailed in Materials and Methods. Extent of migration is scored by measuring the absorbance at 595 nm. Experiments
were done in triplicate and repeated four times. D, RaLP inhibition reduces tumorigenicity of s.c. xenografted melanoma cells. Athymic nu/nu mice were implanted
s.c. with either control GFP-siRNA or RaLP(1)-siRNA WM266-4 cells. Tumor growth is indicated as tumor volume after injection. Tumors were analyzed for RaLP
expression when animals were sacrificed: tumors #1 to #5, corresponding to RaLP(1)-siRNA WM266-4 cells injected animals; tumors #6 to #10, corresponding to
GFP-siRNA WM266-4 cell–injected animals. WM266-4 cell lysate is used as internal control.
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and both IGF-1R and EGFR (Fig. 5A). Growth factor treatment of
serum-starved IGR-37 cells induced receptor and RaLP phosphor-
ylation (Fig. 5B). The latter occurred rapidly (5 min), was short
lasting (declined after 30 min and was almost undetectable after
2 h; Fig. 5C), and depended on the amount of added IGF-1 or EGF
(Fig. 5D). Notably, we did not observe additional phosphotyrosine-
containing polypeptides or anti-EGFR or anti-IGF-1R immunore-
active polypeptides (Fig. 5B) in the anti-RaLP immunoprecipitates,
suggesting that RaLP does not bind activated receptors (confirmed
by in vitro pull-down experiments using GST-RaLP fusion proteins;
data not shown). Blotting of anti-RaLP immunoprecipitates with
anti-Grb2 antibodies revealed the existence of a ligand-inducible
Grb2-RaLP complex (Fig. 5D). Pull-down experiments using GST-
fusion proteins of Grb2 or Grb2-SH2 or Grb2-SH3 domains showed
that the Grb2-RaLP interaction involves phosphorylated RaLP and
the Grb2 SH2 domain (data not shown).
RaLP phosphorylation upon growth factor stimulation was also
investigated in another metastatic melanoma cell line (WM266-4)
and, upon RaLP overexpression, in primary melanocytes and the
RGP WM1575, VGP WM115, and VGP IGR-39 cell lines, obtaining
similar results (data not shown).
RaLP overexpression increases IGF-1– and EGF-induced
MAPK activation and migration in RGP and VGP melanoma
cells. We then investigated if RaLP increases the migratory effects
of IGF-1 and EGF and if it regulates their downstream signaling
pathways (PI3K or Ras). To this end, RaLP (or Shc, as positive
control) was overexpressed into IGR-39 melanoma cells, which
express low levels of both proteins (Fig. 6A). PI3K signaling was
analyzed indirectly by measuring levels of phosphorylated AKT,
a downstream target (30). No differences in AKT activation were
found in control, RaLP-overexpressing, and Shc-overexpressing
IGR-39 cells before or after stimulation with EGF or IGF-1
(Fig. 6D). Likewise, RaLP did not associate with IRS-1, a critical
adaptor protein implicated in AKT activation by PI3K, with the p85
catalytic subunit of PI3K or with Gab1 (data not shown).
Intracellular levels of activated Ras were measured by in vitro
binding assays using the GST-Raf fusion protein (GST-RBD), which
selectively interacts with the active form of Ras (20). Anti-Ras
immunoblots revealed comparable levels of total Ras protein and
higher levels of activated Ras in lysates of RaLP- and Shc-
overexpressing IGR-39 cells treated with EGF or IGF-1 (Fig. 6C).
Accordingly, factor-stimulated RaLP- and Shc-overexpressing IGR-
39 cells also showed increased levels of p-MAPK (Fig. 6D). Notably,
increased levels of active Ras and p-MAPK were also detected in
basal conditions (Fig. 6C and D), consistently with the finding that
overexpressed Shc and RaLP proteins are moderately tyrosine
phosphorylated (Fig. 6B).
Overexpression of RaLP into the IGR-39 cells (and in the RGP
WM1575 cells and in primary melanocytes, which also express low
levels of RaLP; see Fig. S3A) had no effects on proliferation, whereas
it induced a slight (f25%), yet reproducible, increase of serum-
stimulated migration (Fig. S3B ; data not shown). We then tested the
effects of RaLP overexpression on melanoma migration in the
context of EGF and IGF-1 stimulation, using a wound-healing assay.
Serum-starved WM1575 cells were scratched, induced to migrate,
and scored for their capability to reconstitute the cell monolayer.
RaLP-overexpressing WM1575 cells reconstituted the cell mono-
layer faster than control cells in response to serum, IGF-1, or EGF
(Fig. S3C). Together, these data indicate that RaLP expression in
melanoma cells is rate limiting for IGF-1– and EGF-induced
activation of MAPK and for the ability of these growth factors (and
serum) to promote cell migration. Interestingly, IGR-39 cells carry a
mutated allele of B-Raf (31),6 which encodes a constitutively active
serine-threonine kinase, that functions upstream to Ras (32).
Accordingly, MAPK is activated in melanomas with B-Raf
mutations (27). The fact that Ras signaling and cell migration can
Figure 5. RaLP is tyrosine phosphorylated
upon IGF-1 and EGF induction, and it
binds to Grb2. A, IGF-1R and EGFR
expression was evaluated in IGR-39 and
IGR-37 melanoma cell lines. Vinculin was
used as loading control. WB, Western blot.
B, IGF-1 and EGF stimulation of IGR-37
melanoma cells induces receptors and
RaLP tyrosine phosphorylation but not
their physical association. Anti-RaLP,
anti-IGF-1R, and anti-EGFR
immunoprecipitates of IGR-37 cell lysates
were analysed for anti-phosphotyrosine
(pTyr ), anti-RaLP, anti-IGF-1R, and
anti-EGFR immunoreactivity. C, IGR-37
cells were treated with EGF (10 ng/mL) or
IGF-1 (100 ng/mL) at the indicated time
points. Anti-RaLP immunoprecipitates
were probed with anti-pTyr antibody.
D, scalar amount of EGF (1 and 10 ng/mL)
and IGF-1 (10 and 100 ng/mL) induces
increased RaLP phosphorylation in
IGR-37. RaLP immunoprecipitates were
analyzed for anti-pTyr and anti-Grb2
immunoreactivity. Anti-RaLP antibody was
used as control.
6 Our unpublished data.
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be further increased by RaLP overexpression and/or IGF-1/EGF in
IGR-39 cells suggests that mutant B-Raf is not sufficient, per se, to
induce maximal activation of intracellular migratory pathways in
melanomas, including Ras/MAPK.
MAPK is constitutively activated in metastatic WM266
melanoma cells and is not regulated by RaLP. We then wished
to investigate the effects of RaLP silencing on MAPK activation
and migration induced by IGF-1 and EGF, using the WM266-4
metastatic melanoma cell line, which expresses high levels of
endogenous RaLP and also carries a mutated B-Raf allele (33).6
However, at variance with what we observed using the IGR-39 VGP
melanoma cells, serum starvation or treatments with EGF or IGF-1
did not induce modifications of the levels of p-MAPK and p-AKT in
WM266-4 cells (Fig. S4). Likewise, WM266-4 cells did not show any
increased migratory response to EGF and IGF-1, under our
experimental conditions (treatment of serum-starved cells with
0.1, 1, 10 ng/mL EGF or 1, 10, 50 ng/mL IGF-1; data not shown).
Surprisingly, silencing of RaLP expression in WM266-4 metastatic
cells did not modify the basal levels of MAPK (and AKT) activation
either after serum starvation, or upon growth factor treatment
(Fig. S4). The fact that RaLP expression is indispensable for serum-
dependent migration of the same melanoma cells (Fig. 4C)
suggests that RaLP might regulate additional (MAPK independent)
migratory signaling pathways, which are critically activated in
metastatic melanoma cells.
Discussion
The transition from RGP melanomas, which are confined to the
epidermis and yet curable, to VGP melanomas, which penetrate
into the dermis and sub cutis, is critical in the evolution towards
metastatic melanomas (34–40). Growth of RGP melanoma cells is
tightly regulated by exogenous factors, as supplied by the
surrounding keratinocytes and fibroblasts. Accordingly, RGP
melanoma cells are incapable of migration and anchorage-
independent growth in vitro and are not tumorigenic in
immunodeficient mice (40). VGP melanoma cells, instead, have
acquired the properties of factor/anchorage–independent growth
and migration in vitro and develop as metastasizing tumors in
experimental animal models (40). It seems, therefore, that the
critical biological features of the RGP to VGP transition are the
acquisition of migratory competence, growth factor independence,
and invasive potential. We found high levels of RaLP expression in
about half of VGP and metastatic melanomas, compared with nevi
and RGP melanomas. The fact that normal melanocytes express
low levels of RaLP argues against the possibility that RaLP
expression in melanomas merely reflects their melanocytic origin
and suggests that it is instead selected during melanoma genesis,
and that it might be critical for the acquisition of the VGP and/or
metastatic phenotypes. This hypothesis is supported by our finding
that RaLP expression is indispensable for the growth of metastatic
melanomas in vivo .
Figure 6. Tyrosine-phosphorylated RaLP
induces Ras and MAPK activation but does
not activate the AKT signaling pathway.
A, IGR-39 cells were stably infected with
RaLP- and Shc-containing recombinant
vectors. Empty vector was used as control.
RaLP and Shc protein levels were
analyzed by Western blot with anti-RaLP
(left) and anti-Shc (right ) antibodies.
B, total lysates of control (empty vector)
and RaLP- and Shc-overexpressing
IGR-39 cells were stained with anti-Ras
antibody. Lysates of serum-starved
RaLP- and Shc-overexpressing IGR-39
cells were immunoprecipitated with
anti-RaLP (left ) and anti-Shc (right )
antibodies. RaLP and Shc phosphorylation
was analyzed by anti-phosphotyrosine
antibody and compared with cells infected
with empty vector. C, GST pull-down
assay was done with GST-RBD and GST
alone in RaLP- and Shc-overexpressing
IGR-39 as well as in control cells. Cells
were starved for 48 h and then stimulated
with 100 ng/mL IGF-1 and 10 ng/mL EGF
for 10 min. D, IGF-1 and EGF induction
stimulates MAPK phosphorylation in
RaLP- and Shc-overexpressing cells.
RaLP- and Shc-overexpressing IGR-39
cells are stimulated with 100 ng/mL IGF-1
and 10 ng/mL EGF at the indicated time
points. MAPK phosphorylation is revealed
with anti-p-MAPK antibody. Anti-ERK1/2
immunoblot served as loading control.
E, IGF-1 and EGF stimulation does not
activate the PI3K/AKT pathway. RaLP- and
Shc-overexpressing IGR-39 cells were
stimulated with 100 ng/mL IGF-1 and
10 ng/mL EGF at different intervals.
Western blot analysis with anti-p-AKT
antibody reveals that RaLP does not
activate the AKT pathway. Anti-AKT
immunoblot was used as loading control.
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Melanocytes do not possess migratory/invasive properties, thus
posing the question of where RaLP exerts its primary physiologic
function. Preliminary ISH analyses of the mouse embryo (A.
Simeone and LL) showed high levels of RaLP expression early
during development (E7.5-E10.5), in all those territories that derive
from the Neural Crest Cells (NCC) and the neural tube, and that
subsequently (E12.5-16.5) originate the peripheral and the central
nervous system (where RaLP is no longer expressed; ref. 41). NCCs
migrate along dorsoventral and dorsolateral pathways, giving rise
to neurons and glia of the peripheral nervous system, Schwann and
chromaffin cells, and to founder melanoblasts, which then migrate
to the skin where they differentiate into melanocytes (41). It seems,
therefore, that RaLP is expressed in NCC-derived cells in the
developing embryo. RaLP is also expressed in tumors of both
neural crest and neural tube derivation, whereas it is not expressed
in their corresponding mature cells (e.g., peripheral and central
neurons). Interestingly, analysis of a large panel of nonmelanoma
tumor cell lines7 showed expression of RaLP only in rare cases of
gliomas, neuroblastomas, and neuroectodermal tumors, which are
also of neural crest and neural tube derivation. Because one
relevant property of NCCs and of late-stage melanomas is their
ability to migrate, re-expression of RaLP during the RGP to VGP
transition might be selected by the acquired migratory phenotype.
How RaLP regulates migration in melanoma cells remains
undetermined. Several growth factors and cytokines have been
implicated in melanoma progression and, specifically, in the
acquisition of the migratory phenotype of VGP and metastatic
melanomas (24, 42). An accepted view is that the same factors that
tightly control migration of normal melanocytes, nevi and RGP
melanoma cells (through neighboring cells), become highly
expressed in VGP and metastatic melanomas, thus imposing
autocrine growth and migration potential (24). IGF-1 and EGF are
among the most critical of these factors. IGF-1 is a potent
stimulator for cell growth, survival, and migration of RGP and early
VGP melanomas (24, 26, 27, 43, 44); it becomes highly expressed in
late VGP and metastatic melanomas, which acquire autonomous
proliferative and migratory properties (26, 27). Notably, attenuation
of IGF-1 signaling inhibits melanoma migration in vitro or
melanoma growth in vivo , suggesting that autocrine activation of
the IGF-1 signaling pathway is critical during the RGP to VGP
transition (45). Likewise, EGFR signaling is required to maintain the
transformed phenotype of Ras-induced melanomas in vivo (29).
Our data indicate that when overexpressed in RGP or VGP RaLP-
negative melanoma cells, RaLP behaves as a substrate of activated
IGF-1R or EGFR and stimulates migration, suggesting that it
contributes to the cytoplasmic propagation of IGF-1 or EGF
migratory signals in these cells. Analysis of downstream signaling
pathways revealed that RaLP functions upstream to Ras. Ras/
MAPK signaling, however, increases survival, growth, and migra-
tion of melanoma cells, whereas overexpression of RaLP only
affects migration, suggesting that RaLP might regulate additional
migratory pathways (downstream or independent to Ras). Reverse
genetics experiments further supported this hypothesis. In fact,
down-regulation of RaLP expression into RaLP-positive metastatic
melanoma cells markedly reduced their migration potential,
whereas it had no effect on the extent of MAPK activation. These
findings imply that MAPK activation is not sufficient to support
migration of metastatic melanomas and suggest that RaLP
expression activates other critical (MAPK independent) intracellu-
lar migratory pathways. Regardless of the molecular mechanisms,
which need to be further investigated, our findings indicate that
RaLP is a new and apparently highly specific marker for metastatic
melanoma and a biologically relevant target for the development of
novel therapeutic strategies.
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